Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- Working Group Launched under Pharma Industry Vision Meets for 1st Time
March 31, 2022
- Vonvendi Label Revised for Routine Prophylaxis in VWD
March 30, 2022
- Vaccine Chief Horiuchi to Bow Out at March-End
March 30, 2022
- PMD Law Amendment Bill to Enter Diet Debate March 31, CDP’s Counter-Legislation Too
March 30, 2022
- Japan Grants Orphan Status to Tafinlar, Mekinist, and 4 More APIs
March 30, 2022
- Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
- Govt’s Avigan Purchase Was a Result of Pursuing Possible Scenarios: PM
March 29, 2022
- Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
- MHLW Urges Prefectural Govts to Prep for 4th COVID Shot over Next 2 Months
March 28, 2022
- MHLW to Work Out Physician Payment Disclosure Method with Drug Makers towards Amendment of Clinical Research Law
March 28, 2022
- MHLW Panel OKs 84 More Health Damage Claims for COVID-19 Vaccines
March 28, 2022
- Japan Govt OKs 1.3 Trillion Yen Reserve Fund Use for COVID Measures
March 28, 2022
- PMDA Reviewing Safety Risks for Dexamethasone, Teicoplanin
March 28, 2022
- MHLW Study Group Proposes Using Private Data to Monitor Vaccine Distribution and Shortages
March 28, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
- Precedex Gets 1st Designation as Drug for Specific Use
March 25, 2022
- MHLW Study Group Kicks Off Discussions on Use of Pseudonymously Processed Information
March 25, 2022
- Opposition Party Mulls Counter-Legislation against PMD Law Amendment Bill
March 24, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…